James Chih-Hsin Yang, MD, PhD, on Metastatic Nonsquamous NSCLC: Evaluating Pemetrexed and Platinum With or Without Pembrolizumab
2023 ASCO Annual Meeting
James Chih-Hsin Yang, MD, PhD, of the National Taiwan University Hospital and National Taiwan University Cancer Center, discusses the latest data from the phase III KEYNOTE-789 study, which evaluated the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab in the treatment of adults with EGFR tyrosine kinase inhibitor–resistant, EGFR–mutated, metastatic nonsquamous non–small cell lung cancer (NSCLC) (Abstract LBA9000).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
James Chih-Hsin Yang:
Patients who had EGFR mutation, stage four non-small cell lung cancer, the standard of care is tyrosine kinase inhibitors as a first line. When they fail, they have to receive chemotherapy as a standard of care. KEYNOTE-789 is a randomized phase three study, testing whether adding pembrolizumab to the standard chemotherapy is going to help overall survival and progression-free survival.
492 patients who are randomized into two arms. One, pembrolizumab plus end of care chemotherapy versus chemotherapy plus placebo. The co-primary endpoints were progression-free survival and overall survival. There were three interim analysis. Progression-free survival time were done at the interim analysis two.
The hazard ratio was 0.8, which nearly touched the statistical significant P value of boundary 0.0117 and therefore miss the endpoint. The overall survival endpoint was done at the interim analysis three, which was then final analysis 42 months after the last patient's randomized. The overall survival hazard ratio was 0.84, was also statistically not significant.
We also look at the pathological and clinical factors. We try to figure out whether patients with different characteristics can benefit from pembrolizumab adding to chemotherapy. Unfortunately, there was only one factor that seems to help these patients, which is PD-L1 status. Patients who had PD-L1 more than 1%, which is close to 50% of the population, the hazard ratio for overall survival was 0.77. Where those patients who did not have PD-L1 expression, their hazard ratio for overall survival was 0.91. So, we had a study that we cannot change the standard practice, yet the finding that PD-L1 status may help us to choose a patient when asked for future study.
The ASCO Post Staff
Omid Hamid, MD, of The Angeles Clinic & Research Institute, discusses study findings on fianlimab plus cemiplimab-rwlc, which showed clinical activity in patients with advanced melanoma, comparing favorably with other approved combinations of immune checkpoint inhibitors in the same clinical setting. This is the first indication that dual LAG-3 blockade may produce a high level of activity with significant overall response rate after adjuvant anti–PD-1 treatment. A phase III trial of this regimen in treatment-naive patients with advanced melanoma is ongoing (Abstract 9501).
The ASCO Post Staff
Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, of Institut Gustave Roussy, University of Paris-Saclay, discuss findings from the TALAPRO-2 study, which showed that talazoparib plus enzalutamide improved radiographic progression–free survival over standard-of-care enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer and HRR gene alterations. This regimen also delayed the time to deterioration in global health status and quality of life (Abstract 5004).
The ASCO Post Staff
Lisa M. DeAngelis, MD, and Ingo K. Mellinghoff, MD, both of Memorial Sloan Kettering Cancer Center, discuss findings from the INDIGO trial showing that the IDH1/2 inhibitor vorasidenib improves progression-free survival for patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. These data demonstrate the clinical benefit of vorasidenib in this patient population for whom chemotherapy and radiotherapy are being delayed.
The ASCO Post Staff
Amer Methqal Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, discusses phase III findings on the first-in-class telomerase inhibitor imetelstat, which was given to patients with heavily transfusion-dependent non-del(5q) lower-risk myelodysplastic syndromes that are resistant to erythropoiesis-stimulating agents. Imetelstat resulted in a significant and sustained red blood cell (RBC) transfusion independence in 40% of these heavily transfused patients. The response was also durable and accompanied by an impressive median hemoglobin rise of 3.6 g/dL, and seen in patients with and without ring sideroblasts. Importantly, reduced variant allele frequency was observed in the most commonly mutated myeloid genes which correlated with duration of transfusion independence and hemoglobin rise, therefore suggesting a disease-modifying potential of this agent (Abstract 7004).
The ASCO Post Staff
Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses phase II findings from the waveLINE-004 study. It showed that the antibody-drug conjugate zilovertamab vedotin had clinically meaningful antitumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who experienced disease progression after, or have been ineligible for, autologous stem cell transplantation and/or chimeric antigen receptor T-cell therapy (Abstract 7531).
